Clinical Trial Update: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance [Phase 3]

View source ↗

Summary

Phase 3 trial comparing RAD vs VRD induction in newly diagnosed multiple myeloma with response-adapted consolidation and lenalidomide maintenance; current statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Adriamycin (doxorubicin)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Wuerzburg University Hospital | Conditions: Previously Untreated Symptomatic Multiple Myeloma | Phase 3 | Status: UNKNOWN